A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia

Updated 04/26/2024

Status Recruiting

Clinical Trial Summary

The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in participants with generalized myasthenia gravis (gMG).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06282159
Study type	Interventional
Source	Dianthus Therapeutics
Contact	Sammie Kaligotla
Phone	929-999-4055
Email	clinicaltrials@dianthustx.com
Status	Recruiting
Phase	Phase 2
Start date	February 23, 2024
Completion date	December 2027

See also
	Status	Clinical Trial	Phase
	Completed	`NCT02565576` - Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis	Phase 2
	Completed	`NCT04115293` - Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis	Phase 3
	Recruiting	`NCT05737160` - Study of Telitacicept in Generalized Myasthenia Gravis	Phase 3
	Recruiting	`NCT04224506` - A Pilot Study to Explore the Role of Gut Flora in Myasthenia Gravis
	Recruiting	`NCT04431895` - Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study	Early Phase 1
	Recruiting	`NCT05067348` - Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis	Phase 2
	Withdrawn	`NCT03165435` - A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis	Phase 2/Phase 3
	Recruiting	`NCT05214612` - Predictors and Prognostic Factors of Myasthenia Gravis Outcome
	Recruiting	`NCT05868837` - Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)	Phase 3
	Recruiting	`NCT04146051` - Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)	Phase 2
	Completed	`NCT03759366` - A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)	Phase 3
	Completed	`NCT02473952` - A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis	Phase 2
	Completed	`NCT00683969` - A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Controlling Symptoms of Myasthenia Gravis	Phase 3
	Completed	`NCT03304054` - Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG	Phase 3
	Recruiting	`NCT05716035` - Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis	Phase 2/Phase 3